文献速递胸部肿瘤

基于组织学图像的深度学习预测肺癌基因突变:一项多中心回顾性研究

Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.
PubMed 文献 · Lancet Oncol · 2024-12-06

这项多中心回顾性研究开发了无需标注的深度学习人工智能方法DeepGEM,从常规组织学切片预测肺癌驱动基因突变。研究纳入16家中国医院和TCGA数据集的患者,模型在内部、外部多中心、TCGA及淋巴结转移数据集上均显示稳健性能,内部数据集AUC最高达0.97,外部数据集AUC最高达0.91。

要点

  • DeepGEM模型在内部数据集预测基因突变的AUC为0.85-0.97、准确度为0.79-0.99。
  • 多中心外部数据集AUC为0.76-0.91、准确度为0.76-0.97,TCGA数据集AUC为0.82-0.96。
  • 模型可泛化至淋巴结转移活检样本,EGFR的AUC为0.91、KRAS的AUC为0.88。

核心结论

  • 研究开发了基于人工智能的DeepGEM方法,可对基因突变及突变空间分布提供准确、及时和经济的预测。
  • 该方法显示出作为辅助工具指导肺癌患者临床治疗的巨大潜力。

研究设计与样本

  • 多中心回顾性研究,收集2018年1月1日至2022年3月31日在中国16家医院接受活检和多基因二代测序的肺癌患者数据。
  • 排除60例低质量图像患者后,纳入3637例连续患者的3767张图像,其中男性1978例(54.4%)、女性1514例(41.6%)、性别未知145例(4.0%),中位年龄60岁(IQR 52-67)。
  • 内部数据集1716例,外部数据集1718例,淋巴结转移数据集203例;另纳入TCGA公共数据集473例患者、535张切片。
  • 模型为实例级与包级协同监督的多示例学习方法,具有标签消歧设计;在内部数据集训练和初步测试,在外部数据集和TCGA数据集进一步评估。
  • 主要目标为DeepGEM模型在四个预设组(内部留出测试集、多中心外部测试集、TCGA集、淋巴结转移集)中预测基因突变的性能(AUC和准确度)。

主要发现

  • 内部数据集:切除活检样本AUC为0.90(95%CI 0.77-1.00)至0.97(0.93-1.00),准确度为0.91(0.85-0.98)至0.97(0.93-1.00);抽吸活检样本AUC为0.85(0.80-0.91)至0.95(0.86-1.00),准确度为0.79(0.74-0.85)至0.99(0.98-1.00)。
  • 多中心外部数据集:切除活检样本AUC为0.80(95%CI 0.75-0.85)至0.91(0.88-1.00),准确度为0.79(0.76-0.82)至0.95(0.93-0.96);抽吸活检样本AUC为0.76(0.70-0.83)至0.87(0.80-0.94),准确度为0.76(0.74-0.79)至0.97(0.96-0.98)。
  • TCGA数据集(473例患者、535张切片):AUC为0.82(95%CI 0.71-0.93)至0.96(0.91-1.00),准确度为0.79(0.70-0.88)至0.95(0.90-1.00)。
  • 淋巴结转移数据集:EGFR的AUC为0.91(95%CI 0.88-0.94)、准确度为0.85(0.80-0.88);KRAS的AUC为0.88(0.82-0.93)、准确度为0.95(0.92-0.96)。
  • 模型生成空间基因突变图,显示基因突变的空间分布,并显示出对靶向治疗预后预测的潜力。

临床怎么用

  • 原文结论认为该方法作为辅助工具指导肺癌患者临床治疗显示出巨大潜力,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate detection of driver gene mutations is crucial for treatment planning and predicting prognosis for patients with lung cancer. Conventional genomic testing requires high-quality tissue samples and is time-consuming and resource-consuming, and as a result, is not available for most patients, especially those in low-resource settings. We aimed to develop an annotation-free Deep learning-enabled artificial intelligence method to predict GEne Mutations (DeepGEM) from routinely acquired histological slides. METHODS: In this multicentre retrospective study, we collected data for patients with lung cancer who had a biopsy and multigene next-generation sequencing done at 16 hospitals in China (with no restrictions on age, sex, or histology type), to form a large multicentre dataset comprising paired pathological image and multiple gene mutation information. We also included patients from The Cancer Genome Atlas (TCGA) publicly available dataset. Our developed model is an instance-level and bag-level co-supervised multiple instance learning method with label disambiguation design. We trained and initially tested the DeepGEM model on the internal dataset (patients from the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China), and further evaluated it on the external dataset (patients from the remaining 15 centres) and the public TCGA dataset. Additionally, a dataset of patients from the same medical centre as the internal dataset, but without overlap, was used to evaluate the model's generalisation ability to biopsy samples from lymph node metastases. The primary objective was the performance of the DeepGEM model in predicting gene mutations (area under the curve [AUC] and accuracy) in the four prespecified groups (ie, the hold-out internal test set, multicentre external test set, TCGA set, and lymph node metastases set). FINDINGS: Assessable pathological images and multigene testing information were available for 3697 patients who had biopsy and multigene next-generation sequencing done between Jan 1, 2018, and March 31, 2022, at the 16 centres. We excluded 60 patients with low-quality images. We included 3767 images from 3637 consecutive patients (1978 [54·4%] men, 1514 [41·6%] women, 145 [4·0%] unknown; median age 60 years [IQR 52-67]), with 1716 patients in the internal dataset, 1718 patients in the external dataset, and 203 patients in the lymph node metastases dataset. The DeepGEM model showed robust performance in the internal dataset: for excisional biopsy samples, AUC values for gene mutation prediction ranged from 0·90 (95% CI 0·77-1·00) to 0·97 (0·93-1·00) and accuracy values ranged from 0·91 (0·85-0·98) to 0·97 (0·93-1·00); for aspiration biopsy samples, AUC values ranged from 0·85 (0·80-0·91) to 0·95 (0·86-1·00) and accuracy values ranged from 0·79 (0·74-0·85) to 0·99 (0·98-1·00). In the multicentre external dataset, for excisional biopsy samples, AUC values ranged from 0·80 (95% CI 0·75-0·85) to 0·91 (0·88-1·00) and accuracy values ranged from 0·79 (0·76-0·82) to 0·95 (0·93-0·96); for aspiration biopsy samples, AUC values ranged from 0·76 (0·70-0·83) to 0·87 (0·80-0·94) and accuracy values ranged from 0·76 (0·74-0·79) to 0·97 (0·96-0·98). The model also showed strong performance on the TCGA dataset (473 patients; 535 slides; AUC values ranged from 0·82 [95% CI 0·71-0·93] to 0·96 [0·91-1·00], accuracy values ranged from 0·79 [0·70-0·88] to 0·95 [0·90-1·00]). The DeepGEM model, trained on primary region biopsy samples, could be generalised to biopsy samples from lymph node metastases, with AUC values of 0·91 (95% CI 0·88-0·94) for EGFR and 0·88 (0·82-0·93) for KRAS and accuracy values of 0·85 (0·80-0·88) for EGFR and 0·95 (0·92-0·96) for KRAS and showed potential for prognostic prediction of targeted therapy. The model generated spatial gene mutation maps, indicating gene mutation spatial distribution. INTERPRETATION: We developed an AI-based method that can provide an accurate, timely, and economical prediction of gene mutation and mutation spatial distribution. The method showed substantial potential as an assistive tool for guiding the clinical treatment of patients with lung cancer. FUNDING: National Natural Science Foundation of China, the Science and Technology Planning Project of Guangzhou, and the National Key Research and Development Program of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Xiong S, Ren Q, et al. Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study. Lancet Oncol. 2024. PMID: 39653054. doi:10.1016/S1470-2045(24)00599-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。